Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

The influence of probenecid on the metabolism of sorafenib

- candidate number28476
- NTR NumberNTR6967
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR22-jan-2018
- Secondary IDsMEC 17-490 METC Erasmus MC
- Public TitleThe influence of probenecid on the metabolism of sorafenib
- Scientific TitleA study of the effects of probenecid on the pharmacokinetics and pharmacodynamics of sorafenib (PROSORA-study)
- hypothesisWe want to determine the influence and safety of probenecid on sorafenib pharmacokinetics. By inhibiting the OAT6 transporter there might be a faborable effect on Hand-foot syndrome
- Healt Condition(s) or Problem(s) studiedHepatocellular carcinoma, Renal cell carcinoma, Thyroid carcinoma
- Inclusion criteria1. Age ≥ 18 years
2. Histological or cytological confirmed diagnosis of mRCC, HCC or differentiated thyroid carcinoma
3. Start of sorafenib therapy, at least 7 days but nog longer than 14 days prior to start of the study NB. Patients are allowed to have had previous sorafenib therapy or have started with sorafenib.
4. WHO Performance Status ≤ 2 (appendix D)
5. Able and willing to sign the Informed Consent Form prior to screening evaluations
6. Adequate organ function as defined by:
a. Total bilirubin ≤ 1.5 x ULN (except in case of documented Gilbert’s disease)
b. ASAT ≤ 3.0 x ULN (or ≤ 5 x ULN if liver metastases are present)
c. ALAT ≤ 3.0 x ULN (or ≤ 5 x ULN if liver metastases are present)
d. Serum creatinin ≤ 1.5 x ULN
7. Adequate baseline patient characteristics (complete blood count, and serum biochemistry which involves sodium, potassium, creatinin, calculation of creatinin clearance (MDRD), amylase, lipase, calcium, phosphate, AST, ALT, gamma glutamyltranspeptidase (-GT), lactate dehydrogenase (LDH), ALP, total bilirubin, albumin).
- Exclusion criteria1. Use of drugs which may show an increased systemic exposure when taken concomitantly with probenecid. (see appendix C)
2. Patients with known blood dyscrasias, uric acid kidney stones or until an acute gouty attack has subsided.
3. Use of (over the counter) medication or (herbal) supplements which can interact with either sorafenib or probenecid, e.g. by induction or inhibition of CYP3A4, UGT1A9 (see appendix B and C)
4. Unable or unwilling to abstain from grapefruit, grapefruit juice, herbal dietary supplements, and herbal tea during the study
5. Previous use of probenecid during the last 2 weeks prior to sorafenib treatment
6. Contraindications for use of probenecid such as acute gouty attack or porphyria.
7. Unwilling to undergo a skin biopsy
8. A BMI (body mass index) of less than 8.5 and more than 35.
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupCrossover
- TypeSingle arm
- Studytypeintervention
- planned startdate 27-nov-2017
- planned closingdate1-jun-2019
- Target number of participants16
- Interventionssorafenib alone vs sorafenib + probenecid for 14 consecutive days
- Primary outcomeTo demonstrate bioequivalence of sorafenib with probenecid relative to sorafenib without probenecid based on the AUC in patients with unresectable hepatocellular cancer, advanced clear-cell renal cell carcinoma, locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
- Secondary outcome1. Other pharmacokinetic outcomes (i.e. clearance, maximum concentration (Cmax), Maximum steady-state concentration (Cmaxss), Minimal concentration (Cmin), steady-state volume of distribution (Vss) and half-life (t˝)).
2. To evaluate the incidence and severity of side-effects of treatment with sorafenib in absence and presence of probenecid (in particular HFSR) .
3. To evaluate the intracellular concentration of sorafenib in skin in patients treated with sorafenib in absence and presence of probenecid.
4. To determine the influence of HFSR on quality of life
- TimepointsPharmacokinetics and skin-biopsies will be taken at day 1 and day 15. Also an HFSR QoL questionnaire will be taken out at registration, day 1 and day 15.
- Trial web site
- statusopen: patient inclusion
- Sponsor/Initiator Erasmus Medical Center, Rotterdam
- Funding
(Source(s) of Monetary or Material Support)
Erasmus Medical Center
- Publications
- Brief summaryIn this study we want to determine the safety and influence on pharmacokinetics of sorafenib by probenecid. As a secondary outcome we study the influence on HFSR.
- Main changes (audit trail)
- RECORD22-jan-2018 - 15-feb-2018

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar